Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

Q4 2023 Management View CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed ...

At this time, I would like to welcome everyone to the 10X Genomics fourth quarter and full year 2024 earnings conference call. (Operator Instructions). I would now like to turn the conference over to ...

10X Genomics was founded by Serge Saxonov, Ben Hindson, Kevin D. Ness and Eduard Diviu Terradas on July 2, 2012 and is headquartered in Pleasanton, CA.

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales reorganization and grow base of industry users.

Reports Q4 revenue $165.0M, consensus $164.98M. “In 2024, we launched major new products across all three of our platforms and we made changes ...

Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ryskin from ...

"Our team delivered solid sequential revenue growth over last quarter," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We are confident the work we've done throughout 2024 sets us up ...

PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results ...